Industry Overview - The coal industry is experiencing a comprehensive price increase in the domestic market, driven by heightened demand from downstream sectors such as chemicals due to rising oil prices influenced by geopolitical tensions in the Middle East [6][3]. - As of March 27, the spot reference price for thermal coal in the Bohai Rim was 762 RMB/ton, reflecting a weekly increase of 3.39%, while the Qinhuangdao port price was 761 RMB/ton, up 3.54% [6]. - The metallurgical coal market is also seeing price increases, with main coking coal prices at 1750 RMB/ton, up 8.02%, and 1/3 coking coal at 1380 RMB/ton, up 2.99% [6]. Company Analysis: Aimeike (300896.SZ) - Aimeike reported a revenue of 2.453 billion RMB for 2025, a decrease of 18.94%, and a net profit of 1.291 billion RMB, down 34.05% [9]. - The company’s product lines, particularly solution and gel products, saw significant revenue declines of 27.48% and 26.82% respectively, while new freeze-dried powder products generated 208 million RMB [9]. - Aimeike's gross margin was 92.7%, down 1.94 percentage points, and the net profit margin was 53.07%, down 11.59 percentage points, indicating increased operational costs [9]. Investment Recommendations - The projected earnings per share (EPS) for Aimeike from 2026 to 2028 are estimated at 5, 5.41, and 6.06 RMB, respectively, with a current closing price of 118.74 RMB [8]. - The company is focusing on enhancing its product portfolio through independent research and acquisitions, including a recent acquisition of 85% of South Korea's REGEN for 1.9 million USD, which will strengthen its position in the global aesthetic medicine market [7][9]. - Aimeike's strategic initiatives in R&D and mergers are expected to bolster its capabilities in the aesthetic medicine industry, making it a noteworthy investment opportunity despite current performance pressures [7][9].

Investment Rating - The report maintains a "Buy-A" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][7]. Core Insights - The company is facing short-term performance pressure but is expected to benefit from its capabilities in independent research and acquisitions across the entire medical beauty industry chain [1][3]. - The company reported a revenue of 2.453 billion yuan for 2025, a decrease of 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [3][9]. - The company is expanding its product matrix with new products in clinical trials and has made strategic acquisitions to enhance its global presence in the medical beauty market [5][9]. Financial Performance - The company’s revenue for Q4 2025 was 588 million yuan, reflecting a decline of 9.61% year-on-year, while the net profit for the same period was 198 million yuan, down 46.85% [3][4]. - The gross margin for the period was 92.7%, a decrease of 1.94 percentage points, and the net profit margin was 53.07%, down 11.59 percentage points [4][9]. - The company plans to distribute a cash dividend of 8 yuan per 10 shares to all shareholders [3]. Future Projections - The expected earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 5.00 yuan, 5.41 yuan, and 6.06 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23.7, 22.0, and 19.6 [7][9]. - Revenue is projected to recover to 2.702 billion yuan in 2026, with a year-on-year growth of 10.2% [9][11].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.04 [7]. Core Insights - The company is expected to achieve revenue of RMB 2.453 billion in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to the parent company of RMB 1.291 billion, down 34.05% year-on-year. This decline is attributed to the medical beauty industry entering a mature and regulated phase, leading to intensified competition and slowing growth [1][5]. - The company has a rich pipeline of products, with new approvals progressing steadily. The recent approval of a botulinum toxin product and the registration of minoxidil lotion are expected to contribute positively to future revenues [4][5]. - The company is actively expanding its product lines, particularly in the freeze-dried powder category, which has shown significant revenue growth. The introduction of new products is anticipated to create new growth points and potentially restore revenue growth in 2026 [2][5]. Summary by Sections Financial Performance - In 2025, the company reported a gross margin of 92.7%, a decrease of 1.95 percentage points year-on-year. The gross margin for solution products was 93.1%, and for gel products, it was 97.3% [3]. - The sales expense ratio increased to 15.8%, primarily due to higher personnel costs and increased expenses related to sales activities [3]. Product Sales Structure - The revenue from solution injection products was RMB 1.265 billion, down 27.48% year-on-year, accounting for 51.57% of total revenue. Gel injection products generated RMB 890 million, down 26.82%, making up 36.27% of total revenue. Freeze-dried powder injection products contributed RMB 208 million, accounting for 8.48% [2]. Pipeline and New Products - The company has made significant progress in its product pipeline, with several products entering the registration and approval stages. The approval of the botulinum toxin product is particularly noteworthy as it is the seventh compliant product of its kind approved in China [4]. Earnings Forecast and Valuation - The revenue forecast for 2026 is adjusted to RMB 2.829 billion, reflecting a growth of 15.33% year-on-year. The net profit forecast for 2026 is slightly reduced to RMB 1.422 billion, down 14.9% from previous estimates [5][11]. - The company is valued at a price-to-earnings ratio of 33 times, with a target price adjustment reflecting a premium rate [5].

Core Insights - The company reported a revenue of 1.86 billion yuan for the first three quarters of 2025, a year-on-year decrease of 21.5%, and a net profit attributable to shareholders of 1.09 billion yuan, down 31.1% year-on-year [1] - The decline in performance is attributed to industry growth slowdown and intensified competition [1] Financial Performance - Q3 revenue was 570 million yuan, a year-on-year decline of 21.3%, with a net profit of 300 million yuan, down 34.6% year-on-year [1] - The gross margin in Q3 decreased by 1.4 percentage points to 93.2%, while the sales expense ratio increased by 6.4 percentage points to 15.4% [2] - The net profit margin and non-GAAP net profit margin in Q3 fell by 11.0 and 16.5 percentage points to 53.7% and 45.0%, respectively [2] Industry Trends - Industry growth is under pressure due to intensified competition, although the revenue decline in Q3 showed a narrowing compared to Q2 [2] - The company is actively adjusting its sales team and strategies to enhance education for doctors and institutions, aiming for improvement in future performance [2] Product Pipeline and International Expansion - The company has received approval for Minoxidil lotion and has several products at various stages of development, including Lidocaine and Dexamethasone cream, which are under review [3] - The ongoing integration of Regen and global channel expansion is expected to support the company's long-term growth in the global aesthetic medicine market [3] Profit Forecast and Valuation - The profit forecast for 2025-2026 has been revised down by 11% and 5% to 1.65 billion and 1.92 billion yuan, respectively [4] - The current stock price corresponds to a P/E ratio of 29x for 2025 and 25x for 2026, with a target price of 221 yuan, indicating a potential upside of 38% [4]

Core Viewpoint - Aimeike (300896.SZ), a leading player in the medical aesthetics industry, reported a significant decline in revenue and net profit for the first half of 2025, leading to a drop in stock price following the announcement [1][2]. Financial Performance - The company achieved operating revenue of 1.299 billion yuan, a year-on-year decrease of 21.59% [1]. - Net profit attributable to shareholders was 789 million yuan, down 29.57% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 722 million yuan, a decline of 33.70% [1]. - The net cash flow from operating activities was 655 million yuan, down 43.06% year-on-year [1]. - Basic and diluted earnings per share were both 2.62 yuan, a decrease of 29.57% [1]. - The weighted average return on net assets was 10.10%, down 6.52 percentage points from the same period last year [1]. Product Performance - Revenue from solution-type injection products was 744 million yuan, a decrease of 23.79% year-on-year [1]. - Revenue from gel-type injection products was 493 million yuan, down 23.99% year-on-year [1]. - Gross margins for solution-type and gel-type products were 93.15% and 97.75%, respectively [1]. Research and Development - The company invested 157 million yuan in R&D, an increase of 24.47% year-on-year [1]. - Several products, including botulinum toxin injections and lidocaine cream, are in the registration phase, while others are undergoing clinical trials [1]. Asset and Equity Position - As of the end of the reporting period, total assets were 8.765 billion yuan, an increase of 5.09% from the previous year [2]. - Net assets attributable to shareholders were 7.456 billion yuan, a decrease of 4.37% from the previous year [2]. Dividend Distribution - The board approved a profit distribution plan to pay a cash dividend of 12 yuan (including tax) for every 10 shares, with no bonus shares or capital reserve transfers [4]. Legal Matters - The company is involved in arbitration with *ST Suwu regarding the "Tian Yan Needle" and has taken steps to protect its interests in the ongoing legal dispute [5].

Investment Rating - The report maintains a "Recommended" rating for the company [4][6][10]. Core Insights - The company achieved a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, up 5.33% year-on-year [1][4]. - The acquisition of REGEN Biotech for 190 million USD is a strategic move to enhance the company's competitive edge and international presence in the aesthetic medicine market [2][3]. - The company has a robust pipeline of products, with several expected to launch soon, indicating strong growth potential in the medium to long term [3][4]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024 Revenue: 3.026 billion yuan, 2025 Revenue: 3.390 billion yuan (12.0% growth), 2026 Revenue: 3.911 billion yuan (15.4% growth), 2027 Revenue: 4.777 billion yuan (22.1% growth) [4][6]. - 2024 Net Profit: 1.958 billion yuan, 2025 Net Profit: 2.198 billion yuan (12.3% growth), 2026 Net Profit: 2.567 billion yuan (16.8% growth), 2027 Net Profit: 3.168 billion yuan (23.4% growth) [4][6]. - **Valuation Metrics**: - PE ratios for 2025, 2026, and 2027 are projected at 26X, 22X, and 18X respectively [4][6]. - The company’s net profit margin for 2024 is 64.66%, with a slight increase expected in subsequent years [1][6].